NCT05614349 - Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings | Biotech Hunter

Enrollment

797

Participants

Timeline

Start Date

January 16, 2023

Primary Completion Date

April 28, 2025

Study Completion Date

June 28, 2025

Conditions

COVID-19

Interventions

DRUG

Paxlovid

This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.

DRUG

Antioxidant

Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)

Trial Locations (6)

The Governors of the University of Calgary, Calgary

University of British Columbia, Vancouver

The University of Manitoba, Winnipeg

Eastern Health Newfoundland and Labrador, St. John's

Unity Health Toronto, Toronto

The Research Institute of the McGill University Health Centre, Montreal